FINNENCE ▪ THE WIRE FILE
THE WIRE · № 65159
News■ Unclear/unknown
Pharmalittle: We're reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more
KINDNews
DIRECTION■ Unclear/unknown
SOURCES3
ENTITIES1
STORY SIZE3 RECORDS
FIRST SEEN2026-10-05 13:13 UTC
LAST UPDATE2026-10-05 20:15 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Pharma news roundup noting rising M&A; broad sector signal without specifics.
Pharma deal activity is picking up
CATALYST TO WATCH
Announced pharma transactions
MAIN RISK
Roundup lacks concrete deals
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 3 TIMES · FIRST 2026-10-05 13:13 UTC · LAST 2026-10-05 20:15 UTC2026-10-05 13:13 UTCNewsPharmalittle: We're reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more - STATCURRENT RECORD
2026-10-05 18:01 UTCNewsPharmalittle: We're reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more - statnews.com
2026-10-05 20:15 UTCNewsPharma firms closed biopharma buyouts worth over a hundred billion dollars in the first half of the year, racing to replace top selling medicines worth around $400 billion before patents expire. Leah Bennett of Concurrent explains
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
An officer and director proposes selling 560,000 shares of ImmunityBio (NASDAQ: IBRX).2026-10-05 14:22 UTC
An officer and director proposes selling 560,000 shares of ImmunityBio (NASDAQ: IBRX).2026-10-05 14:22 UTC
→CORRELATIONshares Healthcare
What We’re Thinking: A Democratic Senate Takeover? Maybe, Maybe Not2026-10-05 14:25 UTC
What We’re Thinking: A Democratic Senate Takeover? Maybe, Maybe Not2026-10-05 14:25 UTC
→CORRELATIONshares Healthcare
AI in Protein Engineering Market worth $3.82 billion by 20312026-10-05 14:30 UTC
AI in Protein Engineering Market worth $3.82 billion by 20312026-10-05 14:30 UTC
→CORRELATIONshares Healthcare
SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs2026-10-05 14:31 UTC
SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs2026-10-05 14:31 UTC
→CORRELATIONshares Healthcare
I got a $499 body scan to see if I have cancer. Here’s what I learned.2026-10-05 14:35 UTC
I got a $499 body scan to see if I have cancer. Here’s what I learned.2026-10-05 14:35 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.